Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : The Microcap Kitchen: Stocks 5¢ to $5 -- Ignore unavailable to you. Want to Upgrade?

To: GARY P GROBBEL who wrote (43220)	11/16/2005 3:41:56 PM
From: GARY P GROBBEL	Read Replies (1) \| Respond to of 120411

CLRT up .14 to 1.30....why i like it- PHIZER biz.yahoo.com 9mo numbers, deferred rev coming...strong up top...bottom line will come- biz.yahoo.com This deal with DAKO will continue to pay off in many ways- Clarient and DakoCytomation Sign Distribution and Development Agr Clarient and DakoCytomation Sign Distribution and Development Agreement SAN JUAN CAPISTRANO, Calif., and GLOSTRUP, Denmark, July 19 /PRNewswire-FirstCall/ -- Clarient Inc. (Nasdaq: CLRT), a cancer diagnostics services and technology company, and DakoCytomation, one of the world's leading providers of cancer diagnostic tests and automated testing equipment, today jointly announced the signing of a five-year Distribution and Development Agreement that allows DakoCytomation to distribute Clarient's digital cellular imaging and analysis system, called the Chromavision Automated Cellular Imaging System (ACIS), as an adjunct to DakoCytomation's suite of automated diagnostics equipment. The agreement, based on a Letter of Intent between the two companies previously announced on June 9, 2005, enables DakoCytomation to begin distributing ACIS in North America in September 2005 and eventually expand sales globally, covering more than 70 countries worldwide. The agreement also contemplates that the companies will begin developing more advanced integrated cancer diagnostics solutions and invest in the development of a next generation system. Through this partnership, DakoCytomation's market leading staining systems will be marketed with Clarient's proven image analysis technology to help pathologists and physicians make diagnostic and therapeutic decisions. Accurate testing is a crucial factor in determining the appropriate therapy and prognosis of a patient in the fight against cancer, said Jes Ostergaard, President and CEO of DakoCytomation.